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Background: The Community Acquired Pneumonia immunization Trial in Adults (CAPiTA) was conducted
to evaluate 13-valent pneumococcal conjugate vaccine (PCV13) for the prevention of vaccine-type
community-acquired pneumonia (VT-CAP) and vaccine-type invasive pneumococcal disease (VT-IPD)
in adults aged P65 years. Plotting the cumulative number of episodes against time from vaccination
demonstrated that efficacy was evident soon after vaccination and persisted throughout the duration
of the study. This post hoc analysis was performed to quantify the persistence of vaccine efficacy (VE)
of PCV13.
Methods: This was a parallel-group, randomized, placebo-controlled, double-blind trial. Subjects were
enrolled between September 15, 2008 and January 30, 2010 at 101 sites in the Netherlands and
randomized 1:1 to receive a single dose of PCV13 or placebo. The observed accumulation of episodes
for VT-CAP, nonbacteremic/noninvasive VT-CAP (NB/NI-VT-CAP), and VT-IPD over the course of the study
after vaccination was assessed. Post hoc time-to-event analyses of primary and secondary endpoints
were performed. VE behavior over time was derived and effects of treatment, time, and time by treatment
interactions were estimated.
Results: A total of 84,496 individuals were enrolled (PCV13, n = 42,240; placebo, n = 42,256). Cases of
VT-CAP, NB/NI-VT-CAP, and VT-IPD were greater among placebo recipients compared with PCV13
recipients throughout the postvaccination observation period with a periodic rise in cases in the placebo
group that was consistent with varied exposure and ensuing disease over time. There was a significant
difference in disease-free survival among PCV13 recipients compared with placebo recipients for
VT-CAP (log-rank test P = 0.0005), NB/NI VT-CAP (P = 0.0051), and VT-IPD (P = 0.0004). VE ranged from
42.9% to 50.0% for VT-CAP, 36.2% to 48.5% for NB/NI-VT-CAP, and 66.7% to 75.0% for VT-IPD.
Conclusions: The results of this post hoc analysis of the persistence of PCV13 VE in adultsP65 years, indi-
cate that PCV13 was protective over the 5-year duration of the study, with no waning of efficacy
observed.
ClinicalTrials.gov identifier: NCT00744263
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of community-acquired pneumonia (CAP) and
invasive pneumococcal disease (IPD) caused by Streptococcus
pneumoniae is higher in older adults [1–6], and the morbidity
and mortality associated with pneumococcal disease increases
with advanced age [3,5,7–9]. The natural diminution in the local/
innate and adaptive immune systems or responses observed in
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pneumoniae [10]. In addition, CAP exerts a substantial economic
burden on national healthcare systems that has been documented
in Europe [11] and in the United States [12]. Thus, a vaccine that
reduces the prevalence of CAP and IPD in this population could
have public health benefits.
The Community Acquired Pneumonia immunization Trial in
Adults (CAPiTA; ClinicalTrials.gov identifier NCT00744263) was
conducted to evaluate 13-valent pneumococcal conjugate vaccine
(PCV13) for the prevention of vaccine-type community-acquired
pneumonia (VT-CAP) and vaccine-type invasive pneumococcal dis-
ease (VT-IPD) in adults P65 years of age [13]. This was an event-
driven study that targeted at least 130 first episodes of VT-CAP
in subjects who were randomized 1:1 to receive 13-valent pneu-
mococcal conjugate vaccine (PCV13) or placebo. The per-protocol
analysis vaccine efficacy (VE) results (with 95.2% confidence inter-
vals [CIs]) were 46% (22–62%) for VT-CAP, 45% (14–65%) for non-
bacteremic/noninvasive VT-CAP (NB/NI-VT-CAP), and 75% (95%
CI: 41–91%) for first episodes of vaccine-type IPD (VT-IPD).
Although efficacy was demonstrated for all endpoints in both
the per-protocol and modified intent-to-treat (mITT) populations,
the long-term persistence of PCV13 efficacy in older adults is not
currently known. Plotting the cumulative number of episodes
against time after vaccination demonstrated that efficacy was evi-
dent soon after vaccination and persisted throughout the duration
of the study [13]. Determination of VE over a longer period of time
in adultsP65 years is of importance for guiding recommendations
for revaccination. This post hoc analysis of data from the Commu-
nity Acquired Pneumonia immunization Trial in Adults (CAPiTA)
was performed to more precisely quantify the persistence of VE
of PCV13 in adults P65 years of age.2. Methods
2.1. Study design
The Community Acquired Pneumonia immunization Trial in
Adults (CAPiTA) was a parallel-group, randomized, placebo-
controlled, double-blind trial. Subjects were enrolled between
September 15, 2008 and January 30, 2010 at 101 sites in the
Netherlands. Cases of suspected pneumonia and IPD were acquired
between September 15, 2008 and August 28, 2013 at 59 sentinel
centers. Study surveillance ended after identification of at least
130 per-protocol, first episodes of VT CAP. The complete study
design and procedures were previously published [13,14].
2.2. Study participants
Eligible subjects were adultsP65 years of age with no previous
pneumococcal vaccination and who were not immunocompro-
mised. The study was conducted in compliance with Good Clinical
Practice guidelines and was approved by the Central Committee on
Research Involving Human Subjects and by the Ministry of Health,
Welfare and Sport in the Netherlands. Written informed consent
was obtained from all subjects before the performance of any
study-related procedures. The per-protocol population included
participantswhohadanepisodeofCAPor IPDwithanonsetof symp-
toms at least 14 days after vaccination, were eligible for the study,
received a vaccination, were still immunocompetent at the time of
the CAP or IPD episode, and had no other major protocol violations.
2.3. Study procedures
Subjects were randomized 1:1 to receive a single dose of PCV13
or placebo. Cases of pneumonia were diagnosed using standardprocedures including X-rays and laboratory analysis (BinaxNOW
and serotype-specific urinary antigen detection [UAD]). Samples
from sterile and non-sterile sites were assessed by laboratory cul-
ture and positive samples were serotyped. CAP was confirmed
radiologically together with 2 predefined clinical criteria as
described by Bonten and colleagues [13]; IPD was defined as the
presence of S. pneumoniae in a normally sterile site using labora-
tory culture techniques.2.4. Statistical methods
An interim analysis was planned at the time of at least 65 per-
protocol first episodes of confirmed VT-CAP. The study was to be
stopped at the time of the interim analysis if harm was demon-
strated (i.e., an adjusted upper confidence bound of VE <0), or if
clinically significant VE was demonstrated for first confirmed VT
CAP (i.e., an adjusted lower confidence bound >20%) and for first
confirmed NB/NI VT CAP (i.e., an adjusted lower confidence inter-
val >0). The observed accumulation of episodes for VT-CAP, NB/
NI-VT-CAP, and VT-IPD over the course of the study following vac-
cination was plotted. Post hoc Kaplan–Meier time-to-event analy-
ses of the primary and secondary endpoints were performed.
Behavior of VE over time was also derived, and Poisson regression
was used to estimate the effects of treatment, time, and time by
treatment interaction. Analyses were performed using SAS 9.1
(SAS Institute Inc., Cary, NC). Graphical representations of first epi-
sodes of vaccine-type pneumococcal disease over calendar time
and cumulative episodes of vaccine-type pneumococcal disease
over time since vaccination were produced using S-Plus 8.2 (Tibco
Spotfire, Boston, MA).3. Results
3.1. Study population
A total of 84,496 individuals were enrolled in the study (PCV13,
n = 42,240; placebo, n = 42,256) [13]. Baseline characteristics were
similar between the two vaccine groups and were described previ-
ously [13]. Subjects were followed for a mean of approximately
4 years.3.2. Interim analysis
At the interim analysis, which was conducted for the 74 epi-
sodes for which data were available, the VE for the first episode
of per-protocol confirmed VT-CAP was 49.0% (99.48% CI: 2.4%,
75.9%; P = 0.007), which did not meet the requirements for stop-
ping the study (a lower confidence interval exceeding 20%) and
CAP and IPD data acquisition continued until at least 130 per-
protocol, first episodes of VT-CAP were observed.3.3. First episodes of vaccine-type pneumococcal disease over time
The number of cases of VT-CAP, NB/NI-VT-CAP, and VT-IPD
were higher among subjects who received placebo compared with
the number of cases among subjects who received PCV13 through-
out the postvaccination observation period (Fig. 1). There was a
periodic rise in the number of cases in the placebo group that
was consistent with exposure to pneumococcus and ensuing dis-
ease over time with most cases of pneumococcal disease occurring
between September and April. However, these data do not take
into consideration the time of vaccination (September 2008–Jan-
uary 2010).
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Fig. 1. First episodes of vaccine-type pneumococcal disease over calendar time. NB/NI-VT-CAP = nonbacteremic/noninvasive-vaccine-type community-acquired pneumonia;
PCV13 = 13-valent pneumococcal conjugate vaccine; VT-CAP = vaccine-type community-acquired pneumonia; VT-IPD = vaccine-type invasive pneumococcal disease.
Table 1
Cumulative vaccine efficacy estimates in the per-protocol population.
Years since vaccination
(total observed episodes)
Vaccine
efficacy (%)
P-value
VT-CAP 1 (34) 45.5 0.1214
62 (69) 50.0 0.0076
63 (110) 42.9 0.0054
64 (131) 44.1 0.0016
65 (139) 45.6 0.0006
NB/NI-VT-CAP 1 (25) 43.8 0.2295
62 (50) 48.9 0.0328
63 (77) 36.2 0.0675
64 (88) 40.0 0.0246
65 (93) 45.0 0.0067
VT-IPD 1 (8) 66.7 0.2890
62 (15) 75.0 0.0352
63 (24) 66.7 0.0227
64 (33) 73.1 0.0013
65 (35) 75.0 0.0005
NB/NI-VT-CAP = nonbacteremic/noninvasive-vaccine-type community-acquired
pneumonia; VT-CAP = vaccine-type community-acquired pneumonia; VT-
IPD = vaccine-type invasive pneumococcal disease.
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The total number of pneumococcal disease episodes increased
from 34 to 139, from 25 to 93, and from 8 to 35 for VT-CAP, NB/
NI-VT-CAP, and VT-IPD from 1 to 65 years since vaccination
(Table 1). Accounting for time since vaccination, cumulative epi-
sodes of VT-CAP, NB/NI-VT-CAP, and VT-IPD were higher among
subjects who received placebo compared with subjects who
received PCV13 throughout the postvaccination observation period
(Fig. 2). The number of disease episodes among placebo recipients
increased to a greater extent than among PCV13 recipients shortly
after vaccination and remained greater throughout the postvacci-
nation period.
3.5. Estimated disease-free survival
The estimated disease-free survival function is the estimate of
the distribution in time in which subjects in the trial were free
from disease since vaccination. By approximately day 700, the dis-
tributions were separated as indicated by the lack of overlap of 95%
confidence intervals between the PCV13 and placebo groups (see
Supplementary figures in Bonten et al. [13]). At the end of the
study, 99.9% of subjects in the PCV13 group remained disease-
free, whereas <99.7% of subjects in the placebo group remained
disease-free. This analysis was performed to account for the effect
of censoring, with the Kaplan–Meier analyses including the cen-
sored observations as well as the uncensored observations to eval-
uate any shifts in subjects who received PCV13 relative to those
who received placebo. Potential sources of censoring in this study
included death, confirmed loss to follow up, withdrawal, and the
timing of the enrollment periods. There was a significant difference
in time to the first episode among PCV13 recipients compared with
placebo recipients for VT-CAP (log-rank test P = 0.0005), NB/NI VT-
CAP (P = 0.0051), and VT-IPD (P = 0.0004) confirming that the
interpretation remains consistent when censoring of the data is
accounted for in the analysis [13].
3.6. Cumulative vaccine efficacy estimates
Over the five years of the study, VE ranged from 42.9% to 50.0%
for VT-CAP, 36.2–48.5% for NB/NI-VT-CAP, and 66.7–75.0% for VT-
IPD (Table 1). Poisson regression showed statistically significant
treatment effects for VT-CAP (P = 0.008), NB/NI-VT-CAP
(P = 0.0048), and VT-IPD (P = 0.0002), and years since vaccination
effects (P < 0.05 for all endpoints except VT-IPD, P = 0.2339) consis-
tent with vaccine efficacy estimates and natural variation in
observed disease incidence over time. However, time by treatment
interaction was not significant (VT-CAP, P = 0.8565; NB/NI-VT-CAP,P = 0.1541; VT-IPD, P = 0.6352) showing that no significant evi-
dence of vaccine waning was observed.
4. Discussion
This post hoc analysis of PCV13 VE in the Community Acquired
Pneumonia immunization Trial in Adults (CAPiTA) confirmed that
cases of VT-CAP, NB/NI-VT-CAP, and VT-IPD over the postvaccina-
tion study period were greater in subjects who received placebo
compared with subjects who received PCV13. The benefits of
PCV13 vaccination in older adults was further demonstrated by
the significant difference in disease-free survival between PCV13
and placebo recipients for the outcomes of VT-CAP, NB/NI VT-
CAP, and VT-IPD. As the primary and secondary outcomes of the
study described the prevention of first episodes of CAP (and IPD),
the data presented in this post hoc analysis provide a fuller picture
of the effectiveness of PCV13.
The prevention of VT-CAP, NB/NI-VT-CAP, and VT-IPD in sub-
jects was observed shortly after PCV13 vaccination. Interim analy-
sis (at approximately 2 years) did not meet the extremely stringent
requirements for stopping the study, and resulted in the study con-
tinuing until at least 130 per-protocol, first episodes of VT-CAP
were observed. This allowed for this post hoc study of the persis-
tence of protection and demonstration of persistence of VE
throughout the remainder of the study. A waning of VE would be
observed if the frequency of pneumococcal disease episodes for
PCV13 recipients increased to the same extent as those that were
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Fig. 2. Cumulative episodes of vaccine-type pneumococcal disease over time since vaccination. NB/NI-VT-CAP = nonbacteremic/noninvasive-vaccine-type community-
acquired pneumonia; PCV13 = 13-valent pneumococcal conjugate vaccine; VT-CAP = vaccine-type community-acquired pneumonia; VT-IPD = vaccine-type invasive
pneumococcal disease. From N Engl J Med, Bonten et al., Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults, 372:1114–1125. Copyright
Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
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would become parallel, or if the rate of episodes for PCV13 recipi-
ents increased so that the PCV13 curve approached that of the pla-
cebo curve. However, waning of vaccine-type protection was not
observed during the mean follow-up time of approximately
4 years. The pattern of VE observed over time is as expected given
the natural behavior of test statistics (statistical significance is not
expected until an appropriate minimum number of events are
observed). At the time of study design, it was anticipated that at
least 2 years of follow-up would be required with the expected
number of events in the study.
The analysis of the persistence of vaccine efficacy is of particular
importance in older adults as some age-related decreases in post-
vaccination antibody concentrations have been documented for
tetanus and tick-borne encephalitis vaccines [15]. Another post
hoc analysis of the CAPiTA study data suggested a lower VE for
the combined endpoint of VT-CAP and VT-IPD in elderly subjects
[16].
In many countries, the 23-valent polysaccharide vaccine
(PPSV23) has been recommended for administration to older
adults for the prevention of pneumococcal diseases. Although
PPSV23 is considered to be protective against IPD [17] little evi-
dence exists for protection against nonbacteremic pneumonia in
older adults [18] and meta analyses do not provide evidence for
protection in against all-cause pneumonia in this age group
[17,19]. In contrast to the extended vaccine effectiveness of
PCV13 demonstrated in this post hoc analysis, the vaccine effec-
tiveness of PPSV23 has been shown to wane over time after vacci-
nation particularly in the oldest adults (46%, 22% and 13% in
individuals vaccinated <3 years, 3–5 years, and >5 years previ-
ously) [20,21].
Strengths of the study and therefore, for this post-hoc analysis,
included the large size and the length of the follow-up time. Lim-
itations included those associated with post hoc analyses. Addi-
tional limitations included the restriction of the study to
inhabitants of a single country, and the potential overestimation
of VE with the use of the highly-sensitive serotype-specific UAD
assay [13]. The study used a passive data collection mechanism,
and active follow-up of the 84,496 subjects over the course of
the 5-year study for competing risks was not performed.
As older adults are at increased risk for contracting CAP and for
experiencing more serious morbidity from CAP, the reduction in
pneumococcal disease afforded by PCV13 vaccination may provide
clinical and economic benefits, depending on the remaining bur-
den of vaccine-type disease [22]. The results of this post hoc anal-
ysis of the persistence of PCV13 VE in adults P65 years, indicate
that this vaccine was protective over the duration of the study.
No clear evidence of waning of VE was observed. This findingmay have implications for revaccination strategies in the elderly,
and additional immunogenicity data from the Community
Acquired Pneumonia immunization Trial in Adults (CAPiTA) will
help to further guide future vaccination recommendations.
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